CALDERWOOD & HARKNESS LLP
Attorneys at Law 550 South Hope Street, Suite 2900 Los Angeles, California 90071
MEMORANDUM
PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT
TO: James Prentice, Partner, M&A Practice Group Sandra Tung, Senior Counsel, M&A Practice Group Tiffany Rosenthal, Lead Associate, M&A Practice Group Andrew Fitzpatrick, Associate, M&A Practice Group
FROM: Tiffany Rosenthal, Lead Associate, M&A Practice Group
DATE: August 2, 2023
RE: Representations and Warranties Insurance — Summary and Recommendations for Seller (Genome Dx Therapeutics Inc.)
MATTER: GenomeDx / OncuPath™ Divestiture — Calderwood & Harkness Matter No. 1013-00006&A-4471
This memorandum is protected by attorney-client privilege and constitutes attorney work product. It has been prepared solely for the internal use of Calderwood & Harkness LLP and its client, Genome Dx Therapeutics Inc. Distribution, reproduction, or disclosure of this memorandum or its contents to any person or entity not authorized to receive it is strictly prohibited.
Right-click to update Table of Contents
I. Executive Summary
In connection with the proposed $140,000,000 asset purchase of the OncuPath™ companion diagnostics assay line by Meridian Precision Diagnostics, Inc. ("Buyer" or "Meridian" or "MPD") from our client, Genome Dx Therapeutics Inc. ("Seller," "GDT," or the "Company"), a buyer-side representations and warranties insurance ("RWI") policy has been procured from Apex Mutual Insurance Company (the "Insurer" or "Apex Mutual"). The RWI policy (Policy No. RWI-2023-07182) carries an aggregate limit of liability of $28,000,000, which matches the indemnification cap under the Asset Purchase Agreement dated May 11, 2023 (the "APA"), representing 20% of the Total Consideration. The policy retention (self-insured retention, or "SIR") is $1,400,000, which is aligned with the aggregate basket (deductible) under the APA at 1% of Total Consideration. The total premium for the policy is $840,000, calculated at 3% of the $28,000,000 policy limit, split equally between Seller and Buyer at $420,000 each.
The RWI policy is a buyer-side policy, meaning Meridian is the named insured. GDT is not a named insured or additional insured under the policy. However, the policy has a material and beneficial impact on Seller's indemnification exposure and overall risk profile with respect to the transaction. By providing Buyer with a primary source of recovery for covered breaches of Seller's representations and warranties, the RWI policy substantially reduces the likelihood that Buyer will pursue indemnification claims directly against Seller's escrow or seek recourse against Seller beyond the escrow. Furthermore, the policy contains a waiver of subrogation against Seller and its affiliates (except in cases of fraud), which prevents the Insurer from stepping into Buyer's shoes and pursuing Seller for reimbursement of paid claims.
The purpose of this memorandum is to: (a) summarize the key terms and conditions of the RWI policy; (b) analyze the coverage provided by the policy in relation to the indemnification structure set forth in Article IX of the APA; (c) identify coverage gaps, known-matters exclusions, and standard exclusions that may leave Seller exposed to direct indemnification claims; and (d) provide specific, actionable recommendations to protect Seller's interests in connection with the RWI policy and the closing of the transaction, currently targeted for August 8, 2023.
This memorandum should be read in conjunction with the APA (execution version dated May 11, 2023), the Disclosure Schedules thereto, the draft RWI policy binder provided by Apex Mutual, the Closing Funds Flow Memorandum (to be finalized), and the related transaction documents referenced herein.
II. Background and Transaction Context
To provide the appropriate framework for analyzing the RWI policy, we summarize below the key parties, transaction structure, and relevant background facts.
Seller. Genome Dx Therapeutics Inc. ("GDT") is a Delaware corporation headquartered at 4820 Towne Centre Drive, Suite 200, San Diego, California 92121. GDT is a portfolio company of Pinnacle Biosciences Partners Fund III, L.P. ("Pinnacle Fund III"), which holds approximately 68.4% of the outstanding equity interests in GDT. Pinnacle Fund III is managed by its general partner, Pinnacle Biosciences Partners GP III, LLC. Key principals of Pinnacle involved in the transaction include Nathaniel Hargrove, Priya Ramanathan, Dr. Helena Vasquez, Martin Kowalski, and Rebecca Chiang. GDT's board of directors approved the transaction on May 10, 2023, following a competitive auction process.
Buyer. Meridian Precision Diagnostics, Inc. ("Meridian" or "MPD") is a Delaware corporation headquartered at 3700 Meridian Corporate Park Drive, Research Triangle Park, North Carolina 27709. Meridian is a leading precision diagnostics company focused on oncology and immunology companion diagnostics. Meridian's acquisition of the OncuPath™ business is a strategic expansion of its companion diagnostics platform and represents a significant addition to its oncology assay portfolio.
Transaction Structure. The transaction is structured as an asset purchase pursuant to the APA dated May 11, 2023. The assets being acquired include, but are not limited to, the following:
• Fourteen (14) issued United States patents relating to the OncuPath™ platform and related diagnostic methodologies;
• Seven (7) pending United States patent applications;
• Three (3) registered trademarks (OncuPath™ and related marks);
• FDA-cleared in vitro diagnostic assays (510(k) clearance Nos. K201847, K193215, and K210562);
• The pending Premarket Approval ("PMA") supplement for OncuPath-HER3™ (P230014), submitted to the FDA on January 30, 2023;
• GDT's CLIA-certified reference laboratory located at 4820 Towne Centre Drive, Suite 200, San Diego, California 92121 (CLIA ID: 05D2178493);
• All associated customer contracts, supplier agreements, inventory, equipment, and other business assets as specified in Schedule 1.1 to the APA.
Total Consideration. The aggregate purchase price is $140,000,000, consisting of $126,000,000 in cash payable at closing and up to $14,000,000 in contingent earnout consideration, as further described below. The Total Consideration, as defined in the APA, is $140,000,000 for purposes of calculating the indemnification cap, basket, and escrow amounts.
Earnout. The earnout consideration of up to $14,000,000 is payable upon the achievement of two milestones: Milestone 1, consisting of $8,000,000 payable upon FDA clearance or approval of OncuPath-HER3™ by August 8, 2025; and Milestone 2, consisting of $6,000,000 payable upon the assignment of a CMS Healthcare Common Procedure Coding System ("HCPCS") code and the first Medicare reimbursement for OncuPath-HER3™ by August 8, 2026. The earnout is governed by a separate Earnout Agreement attached as an exhibit to the APA.
Timeline. The APA was signed on May 11, 2023, following completion of due diligence and negotiation of definitive documentation. Closing is currently targeted for August 8, 2023, subject to satisfaction of customary closing conditions, including the receipt of all required regulatory consents and third-party approvals. As of the date of this memorandum, we are not aware of any material impediments to closing on the target date.
Advisors and Key Contacts.
• Seller's Counsel: Calderwood & Harkness LLP (this firm).
• Buyer's Counsel: Whitfield Sayer & Gregg LLP (Jonathan Whitfield, lead partner).
• Financial Advisor to Seller: Brindoval Partners LLC (Victor Sandoval, Managing Director).
• Buyer's Acquisition Financing Lender: Summit National Bank, N.A. ($95,000,000 term loan commitment; Karen Delacroix, Managing Director).
• Escrow Agent: Ashgrove Equity Partners Escrow Services, Inc. ($14,000,000 escrow deposit to Account No. 8841-7023-5500).
• Seller's Auditors/Accountants: Haverford & Lane LLP (Douglas Crane, engagement partner) — responsible for carve-out financial statements and preparation of the final closing balance sheet for purposes of the NWC adjustment.
III. APA Indemnification Structure — Overview
Article IX of the APA establishes a comprehensive indemnification framework governing post-closing claims by Buyer against Seller for breaches of representations and warranties, breaches of covenants, and certain specified indemnified matters. Understanding the APA indemnification structure is essential to evaluating the RWI policy's coverage and identifying any gaps between contractual indemnification and insurance protection. The key components of the APA indemnification framework are summarized below.
Indemnification Cap. Seller's aggregate liability for breaches of general representations and warranties is capped at $28,000,000, representing 20% of the $140,000,000 Total Consideration. This cap applies to all general representation and warranty claims in the aggregate but is subject to the exceptions described below for Fundamental Representations and fraud.
De Minimis Threshold. Individual claims for breaches of representations and warranties must exceed $75,000 per claim in order to count toward the aggregate basket. Claims falling below the $75,000 de minimis threshold are disregarded entirely and do not accumulate toward the basket amount. This provision serves to filter out immaterial claims and prevent Buyer from aggregating numerous small claims to reach the basket.
Basket (Aggregate Deductible). The APA employs a tipping basket structure with an aggregate deductible of $1,400,000, representing 1% of Total Consideration. Under a tipping basket, Seller has no liability for breaches of general representations and warranties unless and until the aggregate amount of qualifying claims (i.e., claims exceeding the $75,000 de minimis threshold) exceeds the $1,400,000 basket. Once the aggregate amount of qualifying claims exceeds the basket, the basket "tips" and Buyer is entitled to recover from dollar one — that is, the full amount of qualifying claims, not merely the excess above the basket. This structure is distinguishable from a "true deductible" basket, under which Buyer would recover only amounts in excess of the basket threshold.
Survival Periods. General representations and warranties survive for a period of 18 months from the closing date, commencing on August 8, 2023 and expiring on February 8, 2025. All claims for breaches of general representations must be asserted by written notice delivered prior to the expiration of the survival period. Fundamental Representations, as defined below, are subject to an extended survival period of 60 months from closing, commencing on August 8, 2023 and expiring on August 8, 2028.
Fundamental Representations. Certain representations deemed to be of fundamental importance to the transaction are designated as "Fundamental Representations" under the APA. The Fundamental Representations include, among others, representations as to Seller's organization and authority, due authorization and enforceability, title to the purchased assets, intellectual property ownership, and capitalization. Fundamental Representations are not subject to the $28,000,000 indemnification cap or the $1,400,000 basket. Instead, Seller's aggregate liability for all claims — including Fundamental Representations — is limited only by the Total Consideration of $140,000,000.
Escrow. At closing, $14,000,000 (representing 10% of Total Consideration) will be deposited with Ashgrove Equity Partners Escrow Services, Inc. into Escrow Account No. 8841-7023-5500 (the "Escrow Account"). The escrow serves as a funded indemnification reserve securing Seller's indemnification obligations under the APA. The escrow release schedule is as follows:
• First Escrow Release (12 months post-closing): 50% of the remaining escrow balance is to be released to Seller on August 8, 2024. If no indemnification claims are pending at that time, $7,000,000 will be released.
• Final Escrow Release (18 months post-closing): The remaining escrow balance is to be released to Seller on February 8, 2025, which coincides with the expiration of the survival period for general representations. The release is subject to a holdback for any pending claims that have been asserted but not yet resolved as of the release date, with such holdback amounts released upon resolution of the pending claims.
Escrow as Exclusive Remedy. The APA provides that the escrow is the sole and exclusive remedy for general indemnification claims arising from breaches of non-Fundamental Representations and Warranties. This exclusivity limitation does not apply to claims based on Fundamental Representations, fraud, or willful breach, for which Buyer retains direct recourse against Seller beyond the escrow. The interplay between the escrow, the indemnification cap, and the RWI policy is discussed in greater detail in Section VII below.
IV. RWI Policy — Key Terms
This section summarizes the material terms and conditions of the RWI policy procured by Buyer from Apex Mutual Insurance Company.
A. Insurer and Policy Identification
The RWI policy has been procured from Apex Mutual Insurance Company, a New York-domiciled insurance company. Apex Mutual is a well-established insurer in the transactional risk insurance market, with a current A.M. Best rating of A (Excellent), Financial Size Category XII. The underwriting contact for this policy is Philip Aldridge, Senior Vice President, Transactional Risk Group, located at 175 Water Street, 22nd Floor, New York, New York 10038.
The policy has been assigned Policy No. RWI-2023-07182. The effective date of the policy is the closing date of the transaction, currently anticipated to be August 8, 2023.
B. Named Insured
The RWI policy is a buyer-side policy. Accordingly, Meridian Precision Diagnostics, Inc. is the named insured under the policy. GDT is not a named insured, an additional insured, or a loss payee under the policy. However, as discussed throughout this memorandum, GDT benefits indirectly and materially from the buyer-side RWI structure because: (i) the policy provides Buyer with a primary and independent source of recovery for covered breaches, reducing Buyer's incentive to pursue claims against Seller's escrow; and (ii) the policy contains a waiver of the Insurer's subrogation rights against Seller and its affiliates (except in cases of Seller's fraud), which prevents the Insurer from seeking reimbursement from Seller after paying a covered claim.
C. Policy Limit
The aggregate limit of liability under the RWI policy is $28,000,000. This limit matches the Seller indemnification cap under the APA, which is calculated at 20% of the $140,000,000 Total Consideration. The $28,000,000 limit represents the maximum aggregate amount that Apex Mutual will pay under the policy for all covered claims during the policy period, inclusive of loss amounts, defense costs, and any other insured amounts. There are no per-claim sub-limits imposed under the policy, subject to the specific exclusions and limitations discussed in Sections V and VI below.
D. Retention (Self-Insured Retention / "SIR")
The policy provides for a retention (self-insured retention, or "SIR") of $1,400,000. The retention represents the amount of aggregate losses that the named insured (Buyer) must absorb before the policy responds to any covered claim. The $1,400,000 retention has been intentionally aligned with the $1,400,000 aggregate basket under the APA, ensuring structural consistency between the contractual indemnification framework and the insurance coverage.
Buyer absorbs all losses up to the retention amount before the RWI policy begins to respond. Importantly, the retention does not include a "drop-down" feature — that is, defense costs incurred by Buyer do not erode or reduce the retention. The full $1,400,000 retention must be satisfied through actual indemnifiable losses before the policy becomes active. Once the retention is exhausted, the policy responds for covered losses up to the $28,000,000 aggregate limit.
E. Premium. The total premium for the RWI policy is $840,000, calculated at 3% of the $28,000,000 policy limit. This rate is consistent with current market pricing for buyer-side RWI policies in middle-market M&A transactions, particularly in the life sciences and diagnostics sectors, where underwriting complexity and regulatory risk factors tend to modestly increase premium rates relative to other industries.
The premium has been allocated equally between Seller and Buyer, with each party responsible for $420,000 (50% of the total premium). This 50/50 split was negotiated during the term sheet phase of the transaction and is memorialized in Section 7.14 of the APA. Seller's share of the premium ($420,000) is to be paid at or prior to closing and will be reflected as a line item in the Closing Funds Flow Memorandum currently under preparation. The premium is fully earned and non-refundable upon inception of the policy, regardless of whether any claims are made during the policy period.
F. Coverage Scope
The RWI policy covers losses arising from breaches of Seller's representations and warranties as set forth in Article IV of the APA, as of both the signing date (May 11, 2023) and the closing date (August 8, 2023), subject to the bring-down conditions specified in the APA. Covered losses include compensatory damages, defense costs (including reasonable attorneys' fees and expert fees), and certain consequential damages that arise directly from a covered breach. The policy follows the terms and conditions of the APA with respect to the scope, materiality, and knowledge qualifiers applicable to the representations and warranties, except as otherwise specified in the policy.
The RWI policy follows the same survival periods as the APA for each category of representations. General representations are covered for the 18-month period from closing (through February 8, 2025), and Fundamental Representations are covered for the 60-month period from closing (through August 8, 2028). This alignment ensures that the insurance coverage period matches the contractual indemnification window, providing Buyer with a consistent recovery timeline.
G. Policy Period and Claims Reporting
The RWI policy is a claims-made policy. This means that only claims that are first made against the named insured and reported to the Insurer during the policy period are eligible for coverage. The policy period commences on the effective date (closing, August 8, 2023) and extends through the expiration of the applicable survival period for each category of representations and warranties:
• General Representations: Claims must be first made and reported to Apex Mutual by February 8, 2025 (18 months post-closing).
• Fundamental Representations: Claims must be first made and reported to Apex Mutual by August 8, 2028 (60 months post-closing).
Any claim that is first made or reported after the expiration of the applicable policy period will not be covered, even if the underlying breach occurred during the policy period. The claims-made structure is standard for RWI policies and creates a definitive cutoff for coverage, which benefits Seller by limiting the duration of the insurance tail and providing certainty regarding the timeline for potential claims.
V. Known-Matters Exclusions
A. Definition of "Known Matters"
The RWI policy contains a standard "known matters" exclusion, which excludes from coverage any loss arising from matters actually known to the deal team of the named insured (Buyer) prior to the policy inception date that would reasonably be expected to give rise to a claim under the policy. The "deal team" for purposes of the known-matters exclusion is defined in the policy to include Buyer's officers, directors, and employees who were directly involved in the negotiation, diligence, and execution of the APA, as well as Buyer's external legal counsel (Whitfield Sayer & Gregg LLP) and financial advisors. The known-matters exclusion also encompasses matters that were specifically disclosed in the Disclosure Schedules to the APA dated May 11, 2023, as such disclosures constitute matters within Buyer's knowledge for underwriting purposes.
The rationale for the known-matters exclusion is fundamental to RWI underwriting: the policy is designed to insure against unknown risks — breaches of representations and warranties that are not apparent or anticipated based on the due diligence conducted prior to closing. It is not intended to function as a guaranty of disclosed or known conditions, and the Insurer assumes no liability for matters that were identified and evaluated during the transaction process.
B. Specific Excluded Known Matters
In addition to the general known-matters exclusion, the RWI policy includes an "Excluded Matters Schedule" that identifies specific matters flagged during the underwriting process as excluded from coverage. While the final Excluded Matters Schedule has not yet been formally delivered (and is expected to be included with the final policy within 30 days post-binding), the following categories of matters have been identified during the underwriting process as likely exclusions:
1. Pre-Closing Environmental Liabilities. Environmental liabilities associated with GDT's facilities that are not being conveyed as part of the purchased assets. This exclusion relates to any known or potential environmental contamination, remediation obligations, or regulatory compliance issues at GDT facilities other than the CLIA-certified reference laboratory being transferred.
2. Pending Litigation Matters. Litigation matters disclosed in the Disclosure Schedules to the APA, including any pending or threatened lawsuits, arbitrations, or administrative proceedings identified in Schedule 4.10 (Litigation) as of the signing date.
3. OncuPath-HER3™ PMA Supplement (P230014). Any issues relating to the pending PMA supplement for OncuPath-HER3™, which was submitted to the FDA on January 30, 2023, and remains under review. The Insurer has identified potential regulatory outcome uncertainty associated with this submission, including the risk of a refusal to file, a request for additional clinical data, or an unfavorable FDA determination. The Insurer is not willing to assume the risk of regulatory non-approval or the consequences of any adverse FDA action on the PMA supplement.
4. Patent Chain-of-Title Deficiencies. Any known deficiencies, gaps, or irregularities in the chain of title for any of the 14 issued United States patents or 7 pending patent applications identified during intellectual property due diligence. To the extent that specific chain-of-title issues were flagged in the IP diligence report and disclosed in the Disclosure Schedules, those matters are excluded.
5. CLIA Certificate Non-Compliance. Any disclosed non-compliance issues relating to the CLIA certificate for the reference laboratory located at 4820 Towne Centre Drive, Suite 200, San Diego, California 92121 (CLIA ID: 05D2178493). If CLIA inspection deficiencies, corrective action plans, or regulatory correspondence were disclosed during diligence, those matters fall within the known-matters exclusion.
C. Impact on Seller
The known-matters exclusions have a direct and significant impact on Seller's post-closing risk profile. If Buyer makes a claim under the RWI policy for a matter that falls within the known-matters exclusion (i.e., a matter that was disclosed in the Disclosure Schedules or otherwise known to Buyer's deal team), Apex Mutual will deny coverage for that claim. In such a scenario, Buyer's sole recourse for the excluded matter would be through the contractual indemnification provisions of the APA — specifically, by making a claim against the $14,000,000 escrow or, for Fundamental Representations and fraud, by pursuing Seller directly.
This dynamic creates an important tension for Seller in the preparation of the Disclosure Schedules. On one hand, Seller has an obligation to provide complete and accurate disclosures to qualify the representations and warranties in the APA, and robust disclosure serves as a defense against post-closing breach claims. On the other hand, each matter disclosed in the Disclosure Schedules effectively becomes a "known matter" that is excluded from RWI coverage, which means that Buyer's only recovery source for disclosed matters is Seller's indemnification.
Seller's counsel should ensure that the Disclosure Schedules are thorough, specific, and accurate, but also carefully drafted to avoid overly broad or vague disclosures that may not effectively qualify the applicable representations while nonetheless excluding the matters from RWI coverage. The goal is to achieve the appropriate balance: disclosures that are sufficiently detailed to qualify representations and protect Seller against breach claims, without unnecessarily expanding the universe of known matters excluded from RWI coverage.
VI. Standard Exclusions and Limitations
In addition to the known-matters exclusions discussed in Section V above, the RWI policy contains a number of standard exclusions and limitations that are customary in buyer-side RWI policies. These exclusions are generally non-negotiable and reflect the Insurer's underwriting position on categories of risk that it is unwilling to assume. Each exclusion is summarized below, along with an assessment of its impact on Seller.
A. Fraud and Willful Breach
The RWI policy does not cover losses arising from Seller's fraud or willful breach of representations and warranties. This is the most significant standard exclusion and has direct implications for Seller's exposure profile. Under the APA, Buyer retains full and direct recourse against Seller for claims based on fraud, without application of the $28,000,000 indemnification cap, the $1,400,000 basket, or the escrow exclusivity limitation. Seller's aggregate liability for fraud is limited only by the Total Consideration ($140,000,000). The fraud exclusion in the RWI policy is market-standard, universally applied, and non-negotiable in current market practice.
B. Forward-Looking Covenants
The RWI policy covers only breaches of representations and warranties. It does not extend to breaches of Seller's pre-closing covenants (such as the obligation to operate the business in the ordinary course between signing and closing) or post-closing covenants (such as obligations under the Transition Services Agreement ("TSA"), non-competition and non-solicitation covenants, or cooperation obligations). Buyer retains direct contractual recourse against Seller for any breaches of covenants under the APA, the TSA, or any ancillary agreements, and such claims are not subject to the RWI policy's coverage.
C. Purchase Price Adjustments
Losses arising from the net working capital ("NWC") adjustment mechanism under Section 2.5 of the APA are excluded from the RWI policy. The APA establishes a target NWC of $6,800,000, with a collar of ±$350,000 (i.e., no adjustment is required if final NWC falls within the range of $6,450,000 to $7,150,000). If the final NWC as determined by the closing balance sheet falls outside the collar, a dollar-for-dollar purchase price adjustment applies. The final closing balance sheet is to be prepared by Haverford & Lane LLP (Douglas Crane, engagement partner) within 90 days of closing, with a final determination deadline of November 6, 2023.
NWC disputes — including disputes over the methodology, accounting principles, or final determination of closing NWC — are resolved through the dispute resolution mechanism in Section 2.5 of the APA and are not insurable under the RWI policy. This exclusion is standard and reflects the Insurer's position that purchase price adjustments are post-closing mechanical calculations rather than breaches of representations and warranties.
D. Earnout Disputes
The RWI policy does not cover any disputes relating to the contingent earnout consideration of up to $14,000,000. As described in Section II above, the earnout is structured in two milestones: Milestone 1 ($8,000,000 payable upon FDA clearance or approval of OncuPath-HER3™ by August 8, 2025) and Milestone 2 ($6,000,000 payable upon CMS HCPCS code assignment and first Medicare reimbursement by August 8, 2026). Disputes regarding the achievement of earnout milestones, Buyer's earnout cooperation obligations, or the calculation and payment of earnout amounts are governed by the separate Earnout Agreement and the dispute resolution mechanisms contained therein. These matters are outside the scope of the RWI policy.
E. Tax Representations
Certain tax-related representations may be partially excluded from the RWI policy or subject to sub-limits. In particular, the policy carves out matters relating to the IRC § 1060 purchase price allocation and transfer tax liabilities. The IRC § 1060 allocation is required to be agreed upon by Seller and Buyer within 120 days of closing (by December 6, 2023). The preliminary allocation under discussion contemplates the following categories and amounts:
Any disputes between Seller and Buyer over the final allocation, or tax liabilities resulting from an inconsistent allocation on tax returns, are excluded from RWI coverage. Seller's tax exposure in connection with the allocation should be separately analyzed; we refer the team to Leonard Cross's Tax Structuring Memorandum for a detailed treatment of this issue.
F. Asbestos, ERISA, and Other Standard Carve-Outs
The RWI policy contains standard market exclusions for the following categories of risk, which are customarily excluded from buyer-side RWI policies:
• Asbestos: Losses arising from or related to asbestos or asbestos-containing materials.
• Pollution and Environmental: Losses arising from pollution or environmental contamination, beyond the scope of matters specifically disclosed and addressed in the Disclosure Schedules and the APA.
• ERISA and Benefit Plan Liabilities: Losses arising from underfunded pension obligations, ERISA compliance issues, or other employee benefit plan liabilities, to the extent such liabilities relate to Seller's benefit plans and are not assumed by Buyer.
• Product Liability (Pre-Closing Sales): Losses arising from product liability claims to the extent attributable to sales, distribution, or use of OncuPath™ diagnostic assays prior to the closing date. This exclusion limits coverage for latent product liability exposure related to pre-closing commercial activities.
These exclusions are standard, broadly recognized in the RWI market, and have not been the subject of negotiation in this transaction.
VII. Interplay Between RWI Policy and APA Indemnification
The RWI policy and the APA indemnification framework are designed to operate in concert, with the policy functioning as the primary recovery mechanism for Buyer and the APA indemnification (including the escrow) serving as a secondary or backup source of recovery. This section analyzes the key points of interplay between the policy and the APA indemnification structure.
A. Reduction of Seller's Direct Exposure
In a buyer-side RWI structure, the RWI policy functions as Buyer's primary recourse for covered breaches of Seller's representations and warranties. This structural feature significantly reduces the likelihood that Buyer will pursue indemnification claims directly against Seller's $14,000,000 escrow or seek recovery beyond the escrow. The practical dynamic is straightforward: for any breach of a representation or warranty that constitutes a covered claim under the RWI policy, Buyer has a strong economic incentive to pursue recovery from the Insurer rather than from Seller, particularly because the policy provides $28,000,000 in aggregate coverage — double the amount of the escrow.
The $14,000,000 escrow effectively secures Seller's indemnification obligations under the APA and provides Buyer with a funded reserve. The $28,000,000 RWI policy provides an additional, and from Buyer's perspective primary, recovery source that is independent of Seller's creditworthiness or willingness to pay. Together, the escrow and the RWI policy provide Buyer with aggregate potential recovery of up to $42,000,000 for covered claims (though anti-double-recovery provisions should prevent Buyer from recovering the same loss from both sources).
Critically, if the RWI policy pays a covered claim, Apex Mutual generally has no subrogation rights against Seller (except in cases of Seller fraud). This means that Seller is not at risk of a "back-door" recovery by the Insurer stepping into Buyer's shoes. This subrogation waiver is a critical Seller protection and one of the primary reasons that Seller agreed to share the cost of the RWI premium.
B. Retention / Basket Alignment
The $1,400,000 policy retention is intentionally aligned with the $1,400,000 aggregate basket under the APA. This alignment ensures structural consistency between the contractual and insurance recovery frameworks. In practical terms, Buyer bears the first $1,400,000 of aggregate losses before either the APA indemnification basket "tips" or the RWI policy begins to respond.
Because the APA employs a tipping basket structure, once aggregate qualifying claims exceed $1,400,000, Buyer is entitled to recover from dollar one — i.e., the full amount of qualifying claims, including the first $1,400,000. The RWI policy similarly responds for covered losses once the retention is satisfied, covering the full amount of losses in excess of the retention up to the $28,000,000 aggregate limit.
The practical effect of this alignment is that, for non-excluded, non-known matters, the RWI policy — and not the escrow — will absorb Buyer's losses above the $1,400,000 retention. This dynamic further insulates Seller's escrow from claims, as Buyer's primary recovery source for covered losses above the retention is the RWI policy.
C. Cap Alignment
The $28,000,000 aggregate limit of the RWI policy matches the $28,000,000 indemnification cap under the APA (20% of Total Consideration). This alignment provides a full "back-stop" for Buyer's indemnification rights up to the cap amount, ensuring that the RWI policy can potentially absorb the entirety of Seller's general indemnification exposure.
However, it is critical to note that for Fundamental Representations, Seller's aggregate liability under the APA can exceed the $28,000,000 cap and extend up to the full $140,000,000 Total Consideration. The RWI policy does not cover amounts in excess of $28,000,000, regardless of whether the underlying claim relates to a Fundamental Representation. Accordingly, Seller should be aware that Fundamental Representation claims in excess of $28,000,000 are not insured under the RWI policy, and Seller remains exposed to direct liability for such claims above the policy limit. This gap is discussed further in Section VIII.D below.
D. Escrow Mechanics
The interplay between the escrow and the RWI policy is a critical structural element that affects both Seller's risk profile and the timing of Seller's receipt of escrow funds. The escrow release schedule is as follows:
• First Escrow Release (August 8, 2024): 50% of the remaining escrow balance is released to Seller 12 months after closing. If no indemnification claims have been asserted and are pending as of that date, Seller will receive $7,000,000.
• Final Escrow Release (February 8, 2025): The remaining escrow balance is released to Seller upon expiration of the 18-month survival period for general representations, net of any holdback for pending claims that have been asserted but not yet resolved.
If Buyer recovers from the RWI policy for a covered breach, Buyer should not be entitled to "double recovery" by also seeking reimbursement from the escrow for the same loss. The APA should contain express anti-double-recovery language preventing Buyer from collecting the same loss from both the RWI policy and the escrow. We recommend confirming that this provision has been included in the current drafting of the APA and that it is consistent with the RWI policy's terms. If the anti-double-recovery provision is not clearly articulated, Seller faces the risk that Buyer could assert claims against the escrow for matters that are also covered under the RWI policy, effectively depleting the escrow while simultaneously collecting from the Insurer.
E. Subrogation Waiver
As noted above, the RWI policy includes a waiver of subrogation against Seller and its affiliates, including Pinnacle Biosciences Partners Fund III, L.P. and its general partner, except in cases of Seller's fraud. This waiver is a critical negotiated term that was a condition to Seller's agreement to share the cost of the RWI premium.
Without the subrogation waiver, Apex Mutual — after paying a covered claim to Buyer — could "step into Buyer's shoes" and pursue Seller for reimbursement of the paid claim amount. If this were permitted, the RWI policy would provide no practical benefit to Seller, as Seller would ultimately bear the economic cost of the claim through the Insurer's subrogation action. The subrogation waiver prevents this outcome and ensures that once the Insurer pays a covered claim, Seller is not liable for reimbursement (except where Seller has committed fraud).
The scope of the subrogation waiver should be confirmed to ensure it covers all relevant Seller-side parties, including GDT, Pinnacle Fund III, Pinnacle Biosciences Partners GP III, LLC, and their respective directors, officers, employees, and affiliates. This is addressed further in our recommendations in Section XI.A below.
VIII. Coverage Gaps and Risk Areas for Seller
Despite the significant risk-transfer benefits provided by the buyer-side RWI policy, several coverage gaps and risk areas remain for Seller. Each of these gaps represents a scenario in which Buyer may be unable or unwilling to recover from the RWI policy and instead pursue direct indemnification claims against Seller. This section identifies and analyzes the six most significant coverage gaps and provides recommendations for each.
A. Gap 1: Fraud and Willful Breach Carve-Out
Description. The RWI policy does not insure Buyer against losses arising from Seller's fraud or willful breach of representations and warranties. Under the APA, Buyer retains full recourse against Seller for fraud claims, with no application of the $28,000,000 indemnification cap, the $1,400,000 basket, or the escrow exclusivity limitation. Seller's aggregate liability for fraud is limited only by the Total Consideration ($140,000,000). The fraud exclusion also operates as a carve-out from the subrogation waiver — Apex Mutual retains subrogation rights against Seller for claims arising from Seller's fraud.
Risk Assessment. The fraud carve-out creates a significant risk pathway for Seller. In post-closing disputes, Buyer has an economic incentive to characterize a breach of representations and warranties as "fraud" rather than an ordinary breach, because a fraud characterization would: (i) circumvent the indemnification cap, allowing recovery up to $140,000,000; (ii) bypass the escrow exclusivity limitation, permitting direct claims against Seller; and (iii) eliminate the benefit of the RWI subrogation waiver, potentially exposing Seller to both Buyer's direct claim and the Insurer's subrogation claim. The risk of "fraud creep" — where Buyer alleges fraud to avoid the limitations on ordinary breach claims — is a well-recognized dynamic in post-closing M&A disputes.
Recommendation. Seller's counsel should ensure that the APA includes a clear and narrow definition of "Fraud." Specifically, the definition should be limited to actual, intentional fraud involving a knowing misrepresentation of a material fact with the intent to deceive, and should expressly exclude constructive fraud, negligent misrepresentation, recklessness, and any theory of fraud that does not require scienter and intent to deceive. A narrow fraud definition limits the carve-out from both the indemnification cap and the RWI subrogation waiver, protecting Seller against opportunistic fraud allegations.
B. Gap 2: Known-Matters Exclusion
Description. As discussed in detail in Section V above, any matter disclosed in the Disclosure Schedules to the APA or otherwise known to Buyer's deal team prior to the policy inception date is excluded from coverage under the RWI policy. If a disclosed or known matter gives rise to post-closing losses, the RWI policy will not respond, and Buyer's sole recourse will be against Seller's indemnification obligations under the APA — including the $14,000,000 escrow.
Risk Assessment. This exclusion creates a direct link between the specificity of Seller's disclosures and Seller's post-closing exposure. Matters that are disclosed in the Disclosure Schedules may be excluded from the RWI policy, but if the disclosure is insufficiently specific to qualify the applicable representation, Seller may face a breach claim from Buyer that is not covered by insurance. Conversely, overly broad or vague disclosures may not effectively qualify representations and warranties (leaving Seller exposed to breach claims) while simultaneously excluding the matters from RWI coverage (denying Buyer the insurance recovery and forcing Buyer to pursue the escrow).
Recommendation. Seller's Disclosure Schedules should be thorough, specific, and accurate but carefully drafted. Each disclosure should be sufficiently detailed to qualify the applicable representation and create a clear factual record, while avoiding unnecessary breadth or vagueness. Seller's counsel should review each schedule with the transaction team to confirm completeness and accuracy, and should coordinate with the RWI underwriter's Excluded Matters Schedule to ensure alignment between disclosed matters and excluded matters.
C. Gap 3: No Coverage for Covenant Breaches
Description. The RWI policy covers only breaches of representations and warranties. It does not extend to breaches of Seller's covenants, including post-closing obligations under the Transition Services Agreement, earnout cooperation obligations, NWC adjustment cooperation, non-competition and non-solicitation covenants, or any other contractual covenants in the APA or ancillary agreements.
Risk Assessment. If Buyer asserts a claim based on Seller's alleged breach of a post-closing covenant — such as a failure to perform TSA services in accordance with the agreed-upon service levels, or a failure to cooperate in the preparation of the final closing balance sheet — the RWI policy will not respond. Such claims would be asserted directly against Seller under the APA, and Seller would bear the full exposure for covenant breach claims, subject only to any contractual limitations on liability for covenant breaches.
Recommendation. Seller should ensure that liability for TSA performance is capped at a reasonable level and limited to direct damages (excluding consequential, incidental, and punitive damages). Similarly, Seller's earnout cooperation and NWC cooperation obligations should be clearly defined and bounded, with appropriate limitations on Seller's liability for breach. These protections should be negotiated in the TSA, the Earnout Agreement, and the relevant APA provisions.
D. Gap 4: Fundamental Representations Exposure Above Policy Limit
Description. Fundamental Representations survive for 60 months (through August 8, 2028) and are not subject to the $28,000,000 indemnification cap. Seller's aggregate liability for Fundamental Representation claims (together with all other claims) is limited only by the Total Consideration of $140,000,000. The RWI policy, however, provides coverage only up to its $28,000,000 aggregate limit. Any Fundamental Representation claim that exceeds $28,000,000 in losses would result in uninsured exposure for Seller.
Risk Assessment. In an asset purchase transaction, the Fundamental Representations most likely to give rise to claims include representations as to Seller's authority to consummate the transaction, title to the purchased assets, and intellectual property ownership. While the probability of a Fundamental Representation claim exceeding $28,000,000 is relatively low in the context of this transaction — particularly given the nature of the assets being acquired (primarily intangible assets and a reference laboratory) — the potential magnitude of such a claim could be significant if, for example, a third party successfully challenged GDT's ownership of key patents underlying the OncuPath™ platform.
Recommendation. GDT and Pinnacle Fund III should assess whether to procure excess or difference-in-conditions ("DIC") RWI coverage for Fundamental Representations above the $28,000,000 policy limit. Such coverage would extend protection to the full $140,000,000 Total Consideration or some intermediate amount. A cost-benefit analysis should be conducted, taking into account the premium cost of excess coverage, the probability of a catastrophic Fundamental Representation claim, and the nature and strength of the underlying representations. Based on our preliminary assessment, we believe that excess coverage is likely not justified given the low probability of such claims in an asset purchase context, but the analysis should be documented and the decision formally made by GDT's management and Pinnacle's investment team.
E. Gap 5: Tax and § 1060 Allocation Exclusion
Description. Disputes over the IRC § 1060 purchase price allocation are excluded from RWI coverage. The allocation is to be agreed upon within 120 days of closing (by December 6, 2023). The preliminary allocation, as summarized in Section VI.E above, allocates the $140,000,000 Total Consideration among tangible personal property, real property interests, intellectual property, customer relationships, trademarks, and goodwill. Disagreements between Seller and Buyer over the allocation methodology or the amounts assigned to specific asset categories could result in disputes that are not covered by the RWI policy.
Risk Assessment. The allocation has significant tax implications for both parties. Seller generally prefers a higher allocation to goodwill and capital-gain-eligible assets, while Buyer may prefer a higher allocation to amortizable intangible assets (such as intellectual property and customer relationships) that provide faster tax depreciation/amortization benefits. Disagreements over the allocation could lead to disputes that, if unresolved, may result in inconsistent tax reporting by the parties and potential IRS scrutiny.
Recommendation. Seller should work with Leonard Cross (Tax) and the broader tax advisory team to finalize the § 1060 allocation promptly following closing. The APA should bind both parties to the agreed-upon allocation for tax reporting purposes (a standard provision typically included in Section 2.6 or Section 7.X of the APA). Seller should prioritize resolution of the allocation within the 120-day window to avoid protracted disputes.
F. Gap 6: Policy Period Limitations (Claims-Made Basis)
Description. The RWI policy is a claims-made policy, which means that only claims first made against the named insured and reported to Apex Mutual during the policy period are eligible for coverage. Claims that are first made or reported after the expiration of the applicable policy period — February 8, 2025 for general representations and August 8, 2028 for Fundamental Representations — will not be covered, even if the underlying breach occurred during the policy period.
Risk Assessment. If Buyer fails to timely report a claim to Apex Mutual, coverage will be lost, and Buyer's sole recourse will be against Seller's indemnification obligations under the APA. While the claims-made structure benefits Seller by establishing a definitive coverage cutoff, Seller should be aware that a failure by Buyer to timely report a claim could result in the RWI policy not responding, potentially redirecting the claim to Seller's escrow or direct indemnification.
Recommendation. Buyer should be informed of the importance of timely claims reporting under the RWI policy, and the APA should include a covenant by Buyer to promptly report any potential claim to the Insurer. From Seller's perspective, the claims-made structure is favorable because it limits the tail risk of stale or delayed claims and provides certainty regarding the end date of potential coverage. No action by Seller is required on this point, but awareness of the dynamic is important.
IX. Premium Allocation and Payment Mechanics
The total premium for the RWI policy is $840,000, calculated as 3% of the $28,000,000 aggregate policy limit. The premium is allocated equally between Seller and Buyer, with each party responsible for $420,000 (50% of the total premium). This allocation was negotiated during the term sheet phase and is consistent with prevailing market practice for buyer-side RWI policies, where premium splitting between seller and buyer is common and reflects the mutual benefits that both parties derive from the RWI structure.
Seller's Premium Payment. Seller's share of the premium ($420,000) is to be paid at or prior to closing. This amount will be reflected as a separate line item in the Closing Funds Flow Memorandum currently under preparation, and will be deducted from Seller's closing proceeds or paid by wire transfer directly to Apex Mutual Insurance Company. The wiring instructions for premium payment have been provided by Philip Aldridge and will be included in the Closing Funds Flow Memorandum.
Buyer's Premium Payment. Buyer's share of the premium ($420,000) is to be paid separately by Buyer at or prior to closing. Buyer's premium payment is Buyer's sole responsibility and is not deducted from the purchase price or closing cash consideration payable to Seller.
Non-Refundable Premium. The premium is fully earned and non-refundable upon inception of the policy, regardless of whether any claims are made during the policy period. Neither party is entitled to a refund or pro-rata return of the premium in any circumstances, including early termination of the policy, non-occurrence of claims, or cancellation by mutual agreement.
X. Process and Binding Confirmation
RWI Placement Process. The RWI policy was procured through a buyer-led placement process, which is customary for buyer-side RWI policies. Buyer's insurance broker, in coordination with Buyer's counsel (Whitfield Sayer & Gregg LLP), solicited RWI proposals from multiple insurers and ultimately selected Apex Mutual Insurance Company based on pricing, coverage terms, and the insurer's experience with life sciences and diagnostics transactions. Calderwood & Harkness LLP participated in the placement process on behalf of Seller, including attending underwriting calls to present Seller's representations and warranties and to address questions from the underwriting team regarding the Disclosure Schedules and specific diligence findings.
Underwriting Diligence. Apex Mutual conducted a comprehensive underwriting review, including the following diligence materials:
• Access to and review of the virtual data room, which was opened on March 6, 2023;
• Review of the execution version of the APA dated May 11, 2023;
• Review of the Disclosure Schedules to the APA, including all supplements and updates;
• Review of intellectual property diligence materials, including patent prosecution files, assignment records, freedom-to-operate analyses, and IP ownership opinions;
• Review of carve-out financial statements for the OncuPath™ business, prepared by Haverford & Lane LLP (Douglas Crane, engagement partner);
• Review of regulatory filings, including the 510(k) clearance letters, the pending PMA supplement (P230014), and CLIA certificate documentation;
• Participation in underwriting calls with Seller's management and counsel.
No-Claims Declaration. As a condition to binding the RWI policy, Seller was required to provide a no-claims declaration to Apex Mutual confirming that, as of the date of the declaration, Seller had no knowledge of any facts or circumstances that would give rise to a breach of representations and warranties under the APA or would reasonably be expected to result in a claim under the policy. The no-claims declaration was executed by an authorized officer of GDT and delivered to Apex Mutual in connection with the underwriting process. Seller's counsel reviewed the no-claims declaration prior to execution to confirm its consistency with the Disclosure Schedules and GDT's knowledge as of the date of the declaration.
Binding Confirmation. Calderwood & Harkness LLP delivered a binding confirmation letter to Philip Aldridge at Apex Mutual Insurance Company, dated August 6, 2023, confirming that the policy is to be bound effective as of the closing date (August 8, 2023), subject to satisfaction of all closing conditions under the APA. The binding confirmation letter was delivered via email and overnight courier and constitutes a binding commitment by the Insurer to issue the policy upon the occurrence of closing.
Policy Delivery. The final RWI policy document is expected to be delivered by Apex Mutual within 30 days following the binding date. Upon receipt of the final policy, Calderwood & Harkness LLP will review the policy for consistency with the binding terms, the RWI binder, and the APA, and will advise the team of any discrepancies requiring resolution.
XI. Recommendations for Seller
Based on our analysis of the RWI policy, the APA indemnification structure, and the identified coverage gaps, we provide the following recommendations to protect Seller's interests in connection with the RWI policy and the closing of the transaction.
A. Confirm Anti-Subrogation Language
Calderwood & Harkness LLP should verify that the RWI policy's subrogation waiver explicitly covers the following parties:
• Genome Dx Therapeutics Inc.
• Pinnacle Biosciences Partners Fund III, L.P.
• Pinnacle Biosciences Partners GP III, LLC
• All directors, officers, employees, agents, and affiliates of the foregoing, including specifically Nathaniel Hargrove, Priya Ramanathan, Dr. Helena Vasquez, Martin Kowalski, and Rebecca Chiang.
Without a comprehensive subrogation waiver that expressly covers all Seller-side parties, the benefit of the RWI policy to Seller is illusory. If the subrogation waiver is limited to GDT alone and does not extend to Pinnacle and its principals, the Insurer could pursue subrogation claims against Pinnacle or individual directors and officers, effectively shifting the economic cost of the claim to Seller-side parties despite the existence of the RWI policy. We recommend reviewing the final policy language upon delivery and, if necessary, requesting that Apex Mutual issue an endorsement to expand the subrogation waiver to cover all relevant parties.
B. Narrow Fraud Definition in APA
As discussed in Section VIII.A above, Seller's counsel should confirm that the APA definition of "Fraud" is limited to actual, intentional fraud involving a knowing misrepresentation of a material fact with the intent to deceive. The definition should expressly exclude:
• Constructive fraud;
• Negligent misrepresentation;
• Recklessness or gross negligence (absent actual intent to deceive);
• Any theory of fraud that does not require both scienter and intent to deceive.
A narrow fraud definition serves a dual purpose: it limits the carve-out from the indemnification cap under the APA, and it limits the carve-out from the subrogation waiver under the RWI policy. Both of these limitations are essential to protecting Seller's post-closing risk profile. We recommend confirming the current APA drafting and, if necessary, proposing language that narrows the definition before closing.
C. Anti-Double-Recovery Provision
Seller's counsel should confirm that the APA contains an express provision preventing Buyer from recovering the same loss from both the escrow and the RWI policy. At a minimum, the provision should state that Buyer is not entitled to duplicative recovery from both sources for the same underlying loss. Ideally, the provision should go further and require Buyer to first seek recovery under the RWI policy before accessing the escrow — establishing a "primacy" of the RWI policy over the escrow for covered claims. If Buyer is permitted to access the escrow without first pursuing the RWI policy, Seller's escrow will be depleted for claims that could have been covered by insurance, undermining the risk-transfer benefit of the RWI structure.
We recommend reviewing the current APA drafting for anti-double-recovery language and, if the provision is absent or insufficient, proposing appropriate language before closing.
D. Escrow as Sole and Exclusive Remedy
To the extent possible, Seller should negotiate that the escrow is the sole and exclusive remedy for general indemnification claims arising from breaches of non-Fundamental Representations and Warranties (other than claims for fraud and willful breach). This exclusivity limitation, combined with the buyer-side RWI policy, creates a strong risk-transfer package for Seller:
• For covered claims, Buyer's primary recovery source is the RWI policy;
• For uncovered claims (known matters, excluded matters), Buyer's sole recovery source is the escrow;
• In neither case is Buyer entitled to pursue Seller directly beyond the escrow (except for Fundamental Representations, fraud, and willful breach).
This structure provides maximum insulation for Seller and Pinnacle Fund III from post-closing indemnification exposure and allows for a cleaner distribution of the escrow balance upon the expiration of the survival period.
E. Monitor Excluded Matters Schedule
Calderwood & Harkness LLP should obtain a copy of the final Excluded Matters Schedule from Apex Mutual upon delivery of the policy and cross-reference the schedule against the Disclosure Schedules to the APA. Any discrepancy between the matters listed on the Excluded Matters Schedule and the matters disclosed in the Disclosure Schedules should be flagged and resolved before closing, or as soon as practicable thereafter.